Venture Investors See China Remaining Attractive Despite High Valuations

In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”

Shanghai is ready to go full speed ahead to become a global pharma hub.
Shanghai retains its lure for biotech investors seeking exits through IPOs • Source: Alamy

More from China

More from Focus On Asia